Decision-making considerations for single-dose HPV vaccination, including drivers of schedule adoption or switch: insights from immunisation stakeholders in 19 low-income and middle-income countries
Coupled with the WHO's endorsement, the perceived benefits of single-dose HPVV consistently outweighed the anticipated risks, even when these risks delayed country-level HPVV schedule-related decision-making.
Authors
- Rupali J. Limaye (ORCID: https://orcid.org/0000-0002-3883-9720)
- Joseph G. Rosen (ORCID: https://orcid.org/0000-0003-4991-4033)
- Megan Wysong
- Sunny Roy
- Erica N. Rosser
- Ishani Sheth
- Casey Geddes
Institutions
- Johns Hopkins University (US)
Publication Details
- Journal
- BMJ Global Health
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/bmjgh-2024-018779
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bill and Melinda Gates Foundation
- GAVI Alliance
- National Institute of Mental Health